Subcutaneously delivered treprostinil significantly improves the clinical condition of patients with pulmonary arterial hypertension (PAH), according to a study published in Therapeutic Advances in Respiratory Disease. 

PAH has a relatively high mortality rate, although this has been reduced in recent years due to advances in PAH therapeutics. In addition, medical researchers are better equipped in understanding the biological abnormalities that underpin this disease. 

Treprostinil is a prostacyclin analog that has been used in clinical practice in Argentina for more than 15 years. However, studies on its efficacy and safety are relatively scarce. The authors of the current study thus explored the effects of subcutaneous treprostinil (a route of administration made possible by improvements in terms of the stability and half-life of the drug) on the clinical course of PAH. 


Continue Reading

They recruited patients from a PAH national registry, obtaining information between January 2018 and August 2019. Seven Argentinian healthcare centers were involved. Recruited patients (n=64) had a confirmed diagnosis of PAH for more than 6 months. Study endpoints included functional data (such as the 6-minute walk test) and biochemical variables (such as red blood cell count and pro-brain natriuretic peptide). An echocardiogram was also performed to gauge cardiac performance. 

Read more about PAH etiology 

The researchers reported that patients who were on subcutaneous treprostinil for 12 months had significant improvements in a number of parameters, including the 6-minute walk test, pro-brain natriuretic peptide, and mean pulmonary arterial pressure. In addition, patients on 12 months of treatment had a reduced risk stratification according to guidelines set by the European Respiratory Society and the European Society of Cardiology. 

“Our study suggests that pharmacological treatment with subcutaneous treprostinil is associated with an improvement in several of the parameters analyzed in real clinical practice,” the authors concluded.

Reference

Lescano A, Giacommi G, Botta CE, et al. Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in ArgentinaTher Adv Respir Dis. 2022;16:17534666221132735. doi:10.1177/17534666221132735